Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch

Table 5 Comparison of laboratory finding at 144 weeks in tenofovir disoproxil fumarate to tenofovir amibufenamide / tenofovir disoproxil fumarate groups

144 weeks	TDF to TMF	TMF	P value
WBC	6.20 ± 0.37	6.48 ± 0.27	0.558
Hb	145.57 ± 4.64	148.31 ± 2.92	0.764
PLT	240.50 ± 12.49	224.31 ± 12.05	0.405
ALT	32.71 ± 10.93	28.27 ± 5.24	0.257
AST	24.91 ± 3.67	25.01 ± 2.14	0.845
Cr	72.38 ± 4.95	74.26 ± 2.26	0.414
CLCR	103.07 ± 6.79	101.33 ± 3.50	0.154
PHOS	1.01 ± 0.04	0.97 ± 0.03	0.485
GLU	5.15 ± 0.17	5.82 ± 0.36	0.887
TG	1.56 ± 0.38	1.34 ± 0.14	0.904
CHOL	4.64 ± 0.23	4.47 ± 0.16	0.561
HDL	1.29 ± 0.12	1.29 ± 0.06	0.937
LDL	2.83 ± 0.22	2.78 ± 0.13	0.220
FIB-4	15.38 ± 14.59	1.08 ± 0.13	0.739
CAP	182.22 ± 9.02	189.22 ± 7.8	0.175
miR3	2.27 ± 0.72	2.62 ± 0.44	0.896
RNA	1.46 ± 0.79	0.51 ± 0.25	0.986
DNA	1.24 ± 0.76	0.56 ± 0.33	0.531
HBsAg	3.16 ± 0.17	2.95 ± 0.10	0.849
HBeAg	0.18 ± 0.39	-0.37 ± 0.18	0.865

TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate; WBC: White blood cells; Hb: Hemoglobin; PLT: Platelet; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Cr: Creatinine; CLCR: Creatinine clearance; PHOS: Phosphorus; GLU: Glucose; TG: Triglycerides; CHOL: Cholesterol; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; FIB-4: Fibrosis-4; CAP: C-reactive protein; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; miR3: Hepatitis B virus-microRNA-3.